FAQ

Cyclic Nucleotide Phosphodiesterases, Type 3

Known as: cGMP-Inhibited Phosphodiesterase, cGMP Inhibited Cyclic Nucleotide Phosphodiesterase, Cyclic Nucleotide Phosphodiesterase PDE3 Family 
A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1989-2016
01219892016

Related topics

Related topics

11 relations

Narrower (2)

Cyclic Nucleotide Phosphodiesterases, Type 3ACyclic Nucleotide Phosphodiesterases, Type 3B
In BloodPDE3A geneProcess of secretionadministration & dosage
(More)

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Cyclic Nucleotide Phosphodiesterases, Type 3
physiological aspects
chemical synthesis
standards characteristics
PDE3A gene
Process of secretion

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phosphodiesterase III inhibitor promotes drainage of cerebrovascular β-amyloid
OBJECTIVE Brain amyloidosis is a key feature of Alzheimer's disease (AD). It also incorporates cerebrovascular amyloid β (Aβ) in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Phosphodiesterase III Inhibition Increases cAMP Levels and Augments the Infarct Size Limiting Effect of a DPP-4 Inhibitor in Mice with Type-2 Diabetes Mellitus
We assessed whether phosphodiesterase-III inhibition with cilostazol (Cil) augments the infarct size (IS)-limiting effects of… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Phosphodiesterase III inhibition promotes differentiation and survival of oligodendrocyte progenitors and enhances regeneration of ischemic white matter lesions in the adult mammalian brain.
Vascular dementia is caused by blockage of blood supply to the brain, which causes ischemia and subsequent lesions primarily in… (More)
Is this relevant?
2004
2004
Successful treatment with enoximone for severe poisoning with atenolol and verapamil: a case report.
Combined poisoning with calcium channel blockers (CCBs) and beta-blockers is usually associated with severe hypotension and heart… (More)
Is this relevant?
2001
2001
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
BACKGROUND Phosphodiesterase III inhibitors (PDEIII-Is) improve the hemodynamic status of heart failure via inotropic… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension.
OBJECTIVE To determine whether vasopressin could be effective in treating the hypotension associated with phosphodiesterase III… (More)
Is this relevant?
1998
1998
Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: differences between early and established pulmonary hypertension.
Milrinone and 6-bromo-8(methylamino)imidazo[1,2a]pyrazine-2-carbonitrile [SCA40; phosphodiesterase (PDE) III inhibitors… (More)
Is this relevant?
1997
1997
Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A.
BACKGROUND Phosphodiesterase III (PDE3) inhibitors are inotropic agents used to treat congestive heart failure (CHF) and are less… (More)
Is this relevant?
1993
1993
Effect of phosphodiesterase inhibition with amrinone or theophylline on lipolysis and blood flow in human adipose tissue in vivo as measured with microdialysis.
Phosphodiesterase III (cyclic GMP-inhibited, particulate, low Km) is believed to play a dominant role in the cyclic AMP breakdown… (More)
Is this relevant?
1991
1991
Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
High levels of endogenous plasma catecholamines in patients with severe congestive heart failure induce a down-regulation of the… (More)
Is this relevant?